Craft
Biocon

Biocon

Revenue

₹80.2 B

FY, 2022

Market Capitalization

₹294.1 B

2023-01-20

Biocon Summary

Company summary

Overview
Biocon is a global biopharmaceutical company. It manufactures biologics, biosimilar insulins, and antibodies. The company focuses on the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides.
Type
Public
Status
Active
Founded
1978
HQ
Bengaluru, IN | view all locations
Website
https://www.biocon.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Siddharth Mittal

    Siddharth Mittal, CEO and Managing Director

    • Kiran Mazumdar Shaw

      Kiran Mazumdar Shaw, Executive Chairperson

    • Arun Chandavarkar

      Arun Chandavarkar, Managing Director, Biocon Biologics

    • Jonathan Hunt

      Jonathan Hunt, CEO & Managing Director, Syngene International

    LocationsView all

    12 locations detected

    • Bengaluru, KA HQ

      India

      20th KM, Hosur Road, Electronic City

    • Cambridge, MA

      United States

      245 Main St 2nd floor

    • Bengaluru, KA

      India

      Biocon House, Semicon Park, Electronics City, Phase – II, Hosur Road

    • Hyderabad, TG

      India

    • Visakhapatnam, AP

      India

    • Dublin, D

      Ireland

      9 Clare St

    and 6 others

    Biocon Financials

    Summary financials

    Revenue (Q2, 2023)
    ₹23.2B
    Gross profit (Q2, 2023)
    ₹14.5B
    Net income (Q2, 2023)
    ₹818.0M
    Cash (Q2, 2023)
    ₹14.8B
    EBIT (Q2, 2023)
    ₹2.6B
    Enterprise value
    $337.9B

    Footer menu